Eris Lifesciences growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+8.1%+44.0%+19.2%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+10.1%+50.7%+25.7%
+19.8%+42.6%+17.3%
+72.8%−5.6%+6.1%
+75.4%−10.3%+2.6%
+4.7%−0.2%+92.2%
+19.1%+1.5%+45.1%
−49.5%+119.1%+66.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ERIS₹1,163.60

Eris Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersMANKINDAJANTPHARMTORNTPHARMEMCUREGRANULESCONCORDBIOINDGNCAPLIPOINTMcap ₹16,116 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+19.2+44.0+8.1—
EBITDA Growth—+25.7+50.7+10.1—
EBIT Growth—+17.3+42.6+19.8—
Net Income Growth—+6.1-5.6+72.8—
EPS Growth—+2.6-10.3+75.4—
Total Assets Growth—+92.2-0.2+4.7—
Total Equity Growth—+45.1+1.5+19.1—
Cash from Operations Growth—+66.6+119.1-49.5—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.